Literature DB >> 29285724

Management of Itch in Atopic Dermatitis.

Janelle Pavlis1, Gil Yosipovitch2.   

Abstract

Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. The optimal treatment regimen for atopic itch addresses barrier dysfunction, inflammation, neural hypersensitivity, and the itch-scratch cycle. Topical moisturizers remain the foundation of treatment and should be used by all patients with AD-associated pruritus. Step-wise therapy, from topical anti-inflammatory creams to systemic monoclonal antibodies and immunosuppressants, is recommended. There are multiple adjuvant therapies that can be used, especially to target itch in the setting of minimal skin inflammation. Finally, patient education, sleep management, and stress relief are important components to optimize outcomes. This review assesses the latest advances and treatment recommendations for pruritus in AD. Finally, suggested therapeutic ladders and emerging treatments are discussed.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29285724     DOI: 10.1007/s40257-017-0335-4

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  9 in total

Review 1.  Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives.

Authors:  Shirin Kahremany; Lukas Hofmann; Marco Harari; Arie Gruzman; Guy Cohen
Journal:  Pharmacol Rep       Date:  2021-01-18       Impact factor: 3.024

Review 2.  [Pruritus in atopic dermatitis-comparative evaluation of novel treatment approaches].

Authors:  Svenja Müller; Felix Witte; Sonja Ständer
Journal:  Dermatologie (Heidelb)       Date:  2022-06-10

Review 3.  Strategies for using topical corticosteroids in children and adults with eczema.

Authors:  Stephanie J Lax; Jane Harvey; Emma Axon; Laura Howells; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinéad Langan; Amanda Roberts; Amina Ahmed; Ingrid Muller; Long Chiau Ming; Saumya Panda; Pavel Chernyshov; Ben Carter; Hywel C Williams; Kim S Thomas; Joanne R Chalmers
Journal:  Cochrane Database Syst Rev       Date:  2022-03-11

4.  Pain in Atopic Dermatitis: An Online Population-based Survey.

Authors:  Flavien Huet; Jason Shourick; Sophie Séité; Charles Taïeb; Laurent Misery
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

5.  Antipruritic Effect of Ethyl Acetate Extract from Fructus cnidii in Mice with 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis.

Authors:  Xi Chen; Chan Zhu; Yingge Zhang; Niuniu Yang; Hao Shi; Weiwei Yang; Yan Yang; Jianqiang Liang; Liuzhi Chen; Xueying Zeng; Rijin Cai; Guanyi Wu; Zongxiang Tang
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-06       Impact factor: 2.629

6.  Is Itch Intensity in Atopic Dermatitis Associated with Skin Colonization by Staphylococcus aureus?

Authors:  Leszek Blicharz; Paulina Usarek; Grażyna Młynarczyk; Krzysztof Skowroński; Lidia Rudnicka; Zbigniew Samochocki
Journal:  Indian J Dermatol       Date:  2020 Jan-Feb       Impact factor: 1.494

7.  Skin Care Product Rich in Antioxidants and Anti-Inflammatory Natural Compounds Reduces Itching and Inflammation in the Skin of Atopic Dermatitis Patients.

Authors:  Yu Zhang; Nina Heinemann; Franziska Rademacher; Maxim E Darvin; Christian Raab; Cornelia M Keck; Henning Vollert; Joachim W Fluhr; Regine Gläser; Jürgen Harder; Martina C Meinke
Journal:  Antioxidants (Basel)       Date:  2022-05-28

8.  Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

Authors:  H Saeki; N Baba; K Ito; D Yokota; H Tsubouchi
Journal:  Br J Dermatol       Date:  2021-11-01       Impact factor: 11.113

9.  Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.

Authors:  Hidehisa Saeki; Naoko Baba; Kazuhide Oshiden; Yuji Abe; Hidetsugu Tsubouchi
Journal:  J Dermatol       Date:  2019-11-11       Impact factor: 4.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.